Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso

Last updated: May 28, 2019
Sponsor: Gynuity Health Projects
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03269279
1036
  • Female
  • Accepts Healthy Volunteers

Study Summary

The goal of this study is to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Burkina Faso.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Having an ongoing pregnancy of 13-22 weeks gestation

  • Be willing to undergo surgical completion if necessary

  • Have no contraindications to study procedures, according to provider

  • Be willing and able to consent to participate in the study

  • Be willing to follow study procedures

  • Respect legal indications for obtaining an abortion

Exclusion

Exclusion Criteria:

  • Known allergy to mifepristone or misoprostol/prostaglandin

  • Any contraindications to vaginal delivery, including placenta previa

  • Previous transmural uterine incsion

Study Design

Total Participants: 100
Study Start date:
May 20, 2017
Estimated Completion Date:
December 31, 2019

Connect with a study center

  • CHUSS

    Bobo-Dioulasso,
    Burkina Faso

    Active - Recruiting

  • CMA Boromo

    Boromo,
    Burkina Faso

    Active - Recruiting

  • CHUYO

    Ouagadougou,
    Burkina Faso

    Active - Recruiting

  • CHR Ouahigouya

    Ouahigouya,
    Burkina Faso

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.